Washington Post Exposes Financial Forces Driving GLP-1 Prescribing
A Washington Post investigation reveals firms are spending hundreds of millions to influence doctors' GLP-1 prescribing decisions across the United States.
PepNews
Fifth Circuit Upholds FDA, Restricting Compounded GLP-1 Supply
The Fifth Circuit upheld FDA's shortage determination for semaglutide and tirzepatide, locking in restrictions on compounded GLP-1 supply and reducing patient access.
Lawsuits in Three States Allege Compounded GLP-1s Caused Medical Emergencies
Three patients in three states report serious medical emergencies tied to compounded GLP-1 medications, raising questions about telehealth prescribing and compounding quality control.
BBC Investigation Exposes Gray-Market Retatrutide Supply Chain
BBC News investigates how consumer demand for Eli Lilly's investigational retatrutide is fueling counterfeit sales through unregulated channels ahead of FDA filing.
Preprint Study Documents 652 Gray-Market Retatrutide Patients
A preprint by nference researchers identifies 652 patients who used unapproved retatrutide, with 71.2% of those who had a documented source reporting they obtained it outside a clinical trial, mostly through online vendors.
FDA Warns Five Peptide Vendors as September 8 Response Deadline Nears
FDA warning letters dated August 24 target five online peptide vendors selling unapproved retatrutide and other peptides. A September 8 response deadline approaches.
FDA Updates GLP-1 Compounding Guidance, Flags Fraudulent Labels
FDA guidance documents compounded GLP-1 drugs arriving warm and vials labeled with nonexistent pharmacies, while an existing import alert continues targeting substandard ingredients.
Peer-Reviewed Review Finds Peptide Marketing Outpaces Clinical Evidence
An AJSM review of 565 studies on six widely sold peptides finds marketing outpaces clinical evidence, with arsenic and lead found in some tested products.
FDA Tracks 990 Adverse Events From Compounded GLP-1s
FDA has received 990 adverse-event reports tied to compounded semaglutide and 730+ from compounded tirzepatide as of May 2026, with dosing errors among the problems cited.
FDA Warning Letter Deadline for Five Peptide Vendors Expires September 8
Five online peptide vendors face a September 8 deadline to respond to FDA warning letters citing unapproved drug sales including semaglutide and tirzepatide.
